ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

DEPO-PROVERA
Bladder, kidney, and other urologic cancers
Gynecologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

DEPO-PROVERA Rx

Generic Name and Formulations:
Medroxyprogesterone acetate 400mg/mL; susp for IM inj.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for DEPO-PROVERA:

As adjunctive and palliative treatment of inoperable, recurrent, and metastatic renal carcinoma.

Adult:

Initially 400–1000mg IM every week. If improvement noted and disease stabilized within a few weeks or months, may be possible to maintain at 400mg per month.

Children:

Not established.

Contraindications:

Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease.

Warnings/Precautions:

Risk of bone mineral density (BMD) loss. Evaluate BMD with long-term use or in adolescents. Family history of breast cancer or who have breast nodules (monitor closely). History of depression; monitor and discontinue if serious depression recurs. Diabetes. Conditions aggravated by fluid retention (eg, migraine, epilepsy, asthma). Cardiac or renal dysfunction. Pretreatment physical exam should include Pap smear and lab tests. May mask onset of climacteric. Monitor hepatic function periodically; temporarily interrupt if hepatic dysfunction develops. Discontinue if jaundice or liver dysfunction, visual disturbances, migraine, or thrombotic disorders occur. Pregnancy. Nursing mothers.

Interactions:

May be antagonized by aminoglutethimide. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's wort). May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.

Pharmacological Class:

Progestin.

Adverse Reactions:

Menstrual irregularities (eg, bleeding, amenorrhea, spotting), nausea, edema/fluid retention, facial swelling, weight gain, dizziness, headache, nervousness, corticoid-like effects, hypersensitivity; decreased BMD, acne, inj site reactions (eg, pain/tenderness, persistent atrophy/indentation/dimpling, nodule/lump).

How Supplied:

Vials (2.5mL)—1

Indications for DEPO-PROVERA:

As adjunctive and palliative treatment of inoperable, recurrent, and metastatic endometrial carcinoma.

Adult:

Initially 400–1000mg IM every week. If improvement noted and disease stabilized within a few weeks or months, may be possible to maintain at 400mg per month.

Children:

Not established.

Contraindications:

Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease.

Warnings/Precautions:

Risk of bone mineral density (BMD) loss. Evaluate BMD with long-term use or in adolescents. Family history of breast cancer or who have breast nodules (monitor closely). History of depression; monitor and discontinue if serious depression recurs. Diabetes. Conditions aggravated by fluid retention (eg, migraine, epilepsy, asthma). Cardiac or renal dysfunction. Pretreatment physical exam should include Pap smear and lab tests. May mask onset of climacteric. Monitor hepatic function periodically; temporarily interrupt if hepatic dysfunction develops. Discontinue if jaundice or liver dysfunction, visual disturbances, migraine, or thrombotic disorders occur. Pregnancy. Nursing mothers.

Interactions:

May be antagonized by aminoglutethimide. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's wort). May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.

Pharmacological Class:

Progestin.

Adverse Reactions:

Menstrual irregularities (eg, bleeding, amenorrhea, spotting), nausea, edema/fluid retention, facial swelling, weight gain, dizziness, headache, nervousness, corticoid-like effects, hypersensitivity; decreased BMD, acne, inj site reactions (eg, pain/tenderness, persistent atrophy/indentation/dimpling, nodule/lump).

How Supplied:

Vials (2.5mL)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs